Active matrix metalloproteinases 3 and 9 are independently associated with coronary artery in-stent restenosis

Atherosclerosis

Volumn 207, Issue 2, 2009, Pages 603-607

  Jones, G T ^a   Tarr, G P ^a   Phillips, L V ^a   Wilkins, G T ^a   van Rij, A M ^a   Williams, M J A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Coronary stent; Matrix metalloproteinases; Plasma; Restenosis

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; STROMELYSIN;

ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY STENT; DEMOGRAPHY; DISEASE ASSOCIATION; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; NEW ZEALAND; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; AREA UNDER CURVE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; METALS; MIDDLE AGED; NEW ZEALAND; ODDS RATIO; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; STENTS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME;

EID: 70450237204     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.05.036     Document Type: Article

References (33)

1. Al Suwaidi J., Berger P.B., and Holmes Jr. D.R. Coronary artery stents. JAMA 284 (2000) 1828-1836
2. Holmes Jr. D.R., Leon M.B., Moses J.W., et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109 (2004) 634-640
3. Farkouh M.E., Bansilal S., and Fuster V. Risk profiling patients for selective use of drug-eluting stents is warranted. Nat Clin Pract Cardiovasc Med 4 (2007) 346-347
4. James T.W., Wagner R., White L.A., Zwolak R.M., and Brinckerhoff C.E. Induction of collagenase and stromelysin gene expression by mechanical injury in a vascular smooth muscle-derived cell line. J Cell Physiol 157 (1993) 426-437
5. Bendeck M.P., Zempo N., Clowes A.W., Galardy R.E., and Reidy M.A. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 75 (1994) 539-545
6. Lijnen H.R., Lupu F., Moons L., Carmeliet P., Goulding D., and Collen D. Temporal and topographic matrix metalloproteinase expression after vascular injury in mice. Thromb Haemost 81 (1999) 799-807
7. Forough R., Koyama N., Hasenstab D., et al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res 79 (1996) 812-820
8. Cho A., and Reidy M.A. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 91 (2002) 845-851
9. Cedro K., Radomski A., Radomski M.W., Ruzyllo W., and Herbaczynska-Cedro K. Release of matrix metalloproteinase-9 during balloon angioplasty in patients with stable angina. A preliminary study. Int J Cardiol 92 (2003) 177-180
10. Hojo Y., Ikeda U., Katsuki T., Mizuno O., Fujikawa H., and Shimada K. Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 161 (2002) 185-192
11. Nikkari S.T., Geary R.L., Hatsukami T., et al. Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinases-1 in restenosis after carotid endarterectomy. Am J Pathol 148 (1996) 777-783
12. Ge J., Shen C., Liang C., Chen L., Qian J., and Chen H. Elevated matrix metalloproteinase expression after stent implantation is associated with restenosis. Int J Cardiol 112 (2006) 85-90
13. Jones G.T., Kay I.P., Chu J.W., et al. Elevated plasma active matrix metalloproteinase-9 level is associated with coronary artery in-stent restenosis. Arterioscler Thromb Vasc Biol 26 (2006) e121-e125
14. Ellis S.G., Vandormael M.G., Cowley M.J., et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 82 (1990) 1193-1202
15. Mehran R., Dangas G., Abizaid A.S., et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 100 (1999) 1872-1878
16. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
17. Castellazzi M., Tamborino C., Fainardi E., et al. Effects of anticoagulants on the activity of gelatinases. Clin Biochem (2007)
18. Pepe M.S., Cai T., and Longton G. Combining predictors for classification using the area under the receiver operating characteristic curve. Biometrics 62 (2006) 221-229
19. Raffetto J.D., and Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol (2007)
20. Farb A., Sangiorgi G., Carter A.J., et al. Pathology of acute and chronic coronary stenting in humans. Circulation 99 (1999) 44-52
21. Virmani R., and Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 10 (1999) 499-506
22. Feldman L.J., Mazighi M., Scheuble A., et al. Differential expression of matrix metalloproteinases after stent implantation and balloon angioplasty in the hypercholesterolemic rabbit. Circulation 103 (2001) 3117-3122
23. Li C., Cantor W.J., Nili N., et al. Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor. J Am Coll Cardiol 39 (2002) 1852-1858
24. Johnson C., and Galis Z.S. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 24 (2004) 54-60
25. Turner N.A., Hall K.T., Ball S.G., and Porter K.E. Selective gene silencing of either MMP-2 or MMP-9 inhibits invasion of human saphenous vein smooth muscle cells. Atherosclerosis 193 (2007) 36-43
26. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 (2003) 827-839
27. Cook N. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115 (2007) 928-935
28. Chakraborti S., Mandal M., Das S., Mandal A., and Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253 (2003) 269-285
29. Tayebjee M.H., Lip G.Y., Blann A.D., and Macfadyen R.J. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res 115 (2005) 205-210
30. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
31. Windecker S., and Juni P. Safety of drug-eluting stents. Nat Clin Pract Cardiovasc Med 5 (2008) 316-328
32. Aronow H.D., Steinhubl S.R., Brennan D.M., Berger P.B., and Topol E.J. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 157 (2009) 369-374
33. Kaiser C., Brunner-La Rocca H.P., Buser P.T., et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366 (2005) 921-929